Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series
- PMID: 30165986
- DOI: 10.1016/j.jacc.2018.06.046
Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series
Abstract
People who maintain ideal cardiovascular heath have a low lifetime risk of cardiovascular disease. Therefore, encouraging people to achieve ideal cardiovascular health represents an important opportunity to improve the prevention of cardiovascular disease. However, preventing cardiovascular disease by promoting ideal cardiovascular health requires shifting the focus from treating disease after it develops to preventing cardiovascular events before they happen by slowing the progression of atherosclerosis. Because atherogenic lipoproteins play a central causal role in the initiation and progression of atherosclerosis, maintaining optimal lipid levels is necessary to achieve ideal cardiovascular health. This review describes the cumulative effect of lipid-carrying lipoproteins on the risk of cardiovascular disease, estimates the magnitude of the clinical benefit that can be achieved by maintaining optimal lipid levels, identifies the most effective timing for implementing strategies designed to achieve optimal lipid levels, and provides a clinical pathway to help people achieve the lipid levels necessary for ideal cardiovascular health.
Keywords: apolipoproteins; cholesterol; low-density lipoproteins; population; risk; total burden.
Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Republished in
-
Reprint of: Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series.J Am Coll Cardiol. 2018 Dec 11;72(23 Pt B):2980-2995. doi: 10.1016/j.jacc.2018.10.021. J Am Coll Cardiol. 2018. PMID: 30522632 Review.
Similar articles
-
Reprint of: Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series.J Am Coll Cardiol. 2018 Dec 11;72(23 Pt B):2980-2995. doi: 10.1016/j.jacc.2018.10.021. J Am Coll Cardiol. 2018. PMID: 30522632 Review.
-
A Reappraisal of the Lipid Hypothesis.Am J Med. 2018 Sep;131(9):993-997. doi: 10.1016/j.amjmed.2018.04.027. Epub 2018 May 10. Am J Med. 2018. PMID: 29752904 No abstract available.
-
Causal Effect of Lipids and Lipoproteins on Atherosclerosis: Lessons from Genomic Studies.Cardiol Clin. 2018 May;36(2):203-211. doi: 10.1016/j.ccl.2017.12.001. Cardiol Clin. 2018. PMID: 29609749 Review.
-
Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.J Am Coll Cardiol. 2013 Dec 10;62(23):2178-84. doi: 10.1016/j.jacc.2013.07.081. Epub 2013 Sep 4. J Am Coll Cardiol. 2013. PMID: 24013058 Clinical Trial.
-
Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology.Circ Res. 2016 Feb 19;118(4):547-63. doi: 10.1161/CIRCRESAHA.115.306249. Circ Res. 2016. PMID: 26892957 Review.
Cited by
-
Efficacy of Traditional Anti-lipidemic Drugs in Lowering Lipoprotein(a) Levels: A Systematic Review.Cureus. 2024 Sep 20;16(9):e69824. doi: 10.7759/cureus.69824. eCollection 2024 Sep. Cureus. 2024. PMID: 39435209 Free PMC article. Review.
-
Gender-specific association between a lipid composite index and asthma among US adults: insights from a population-based study.Lipids Health Dis. 2024 Oct 30;23(1):353. doi: 10.1186/s12944-024-02338-z. Lipids Health Dis. 2024. PMID: 39478611 Free PMC article.
-
Functionalized Periodic Mesoporous Silica Nanoparticles for Inhibiting the Progression of Atherosclerosis by Targeting Low-Density Lipoprotein Cholesterol.Pharmaceutics. 2024 Jan 4;16(1):74. doi: 10.3390/pharmaceutics16010074. Pharmaceutics. 2024. PMID: 38258085 Free PMC article.
-
The Cardiac Lipidome in Models of Cardiovascular Disease.Metabolites. 2020 Jun 17;10(6):254. doi: 10.3390/metabo10060254. Metabolites. 2020. PMID: 32560541 Free PMC article. Review.
-
Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside.Drug Des Devel Ther. 2021 May 10;15:1955-1963. doi: 10.2147/DDDT.S251865. eCollection 2021. Drug Des Devel Ther. 2021. PMID: 34007155 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical